Send to

Choose Destination
See comment in PubMed Commons below
Int J Mol Sci. 2015 Jun 19;16(6):14122-42. doi: 10.3390/ijms160614122.

Circulating Cell-Free Tumour DNA in the Management of Cancer.

Author information

  • 1Director Pathology, Genomics for Life, Herston 4006, Australia.
  • 2School of Medicine, Griffith University, Gold Coast 4215, Australia.
  • 3Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia 4067, Australia.
  • 4Laboratory Director, Genomics for Life, Herston 4006, Australia.


With the development of new sensitive molecular techniques, circulating cell-free tumour DNA containing mutations can be identified in the plasma of cancer patients. The applications of this technology may result in significant changes to the care and management of cancer patients. Whilst, currently, these "liquid biopsies" are used to supplement the histological diagnosis of cancer and metastatic disease, in the future these assays may replace the need for invasive procedures. Applications include the monitoring of tumour burden, the monitoring of minimal residual disease, monitoring of tumour heterogeneity, monitoring of molecular resistance and early diagnosis of tumours and metastatic disease.


cell-free DNA; cell-free tumour DNA; colorectal carcinoma; liquid biopsy; melanoma; minimal residual disease; non-small cell lung cancer

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
    Loading ...
    Support Center